Name | Number of supported studies | Average coverage | |
---|---|---|---|
amacrine cell | 4 studies | 36% ± 23% | |
oligodendrocyte precursor cell | 4 studies | 29% ± 8% | |
glycinergic amacrine cell | 3 studies | 38% ± 6% |
Insufficient scRNA-seq data for expression of CACNG5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 85% | 19.06 | 2239 / 2642 | 27% | 1.63 | 193 / 705 |
pancreas | 42% | 3.47 | 138 / 328 | 6% | 0.12 | 10 / 178 |
spleen | 18% | 1.50 | 44 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 15% | 0.62 | 12 / 80 |
kidney | 8% | 0.46 | 7 / 89 | 4% | 0.14 | 36 / 901 |
intestine | 8% | 0.42 | 79 / 966 | 1% | 0.03 | 6 / 527 |
uterus | 2% | 1.28 | 4 / 170 | 5% | 0.35 | 22 / 459 |
ovary | 3% | 0.12 | 5 / 180 | 3% | 0.14 | 14 / 430 |
thymus | 4% | 0.23 | 29 / 653 | 0% | 0.02 | 3 / 605 |
adrenal gland | 0% | 0 | 0 / 258 | 5% | 0.19 | 11 / 230 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.54 | 2 / 45 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.05 | 1 / 29 |
prostate | 3% | 0.16 | 7 / 245 | 0% | 0 | 0 / 502 |
skin | 0% | 0.01 | 5 / 1809 | 3% | 0.10 | 12 / 472 |
lung | 0% | 0.01 | 1 / 578 | 2% | 0.07 | 26 / 1155 |
stomach | 1% | 0.03 | 3 / 359 | 1% | 0.19 | 2 / 286 |
esophagus | 0% | 0.01 | 3 / 1445 | 1% | 0.06 | 2 / 183 |
breast | 1% | 0.03 | 3 / 459 | 1% | 0.03 | 6 / 1118 |
adipose | 1% | 0.04 | 8 / 1204 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 0% | 0.02 | 2 / 504 |
blood vessel | 0% | 0.02 | 4 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.01 | 2 / 929 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.01 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 0% | 0 | 0 / 406 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051968 | Biological process | positive regulation of synaptic transmission, glutamatergic |
GO_0019226 | Biological process | transmission of nerve impulse |
GO_0099590 | Biological process | neurotransmitter receptor internalization |
GO_2000311 | Biological process | regulation of AMPA receptor activity |
GO_0070588 | Biological process | calcium ion transmembrane transport |
GO_0098970 | Biological process | postsynaptic neurotransmitter receptor diffusion trapping |
GO_0098943 | Biological process | neurotransmitter receptor transport, postsynaptic endosome to lysosome |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0098839 | Cellular component | postsynaptic density membrane |
GO_0032281 | Cellular component | AMPA glutamate receptor complex |
GO_0014069 | Cellular component | postsynaptic density |
GO_0005245 | Molecular function | voltage-gated calcium channel activity |
GO_0015075 | Molecular function | monoatomic ion transmembrane transporter activity |
GO_0016247 | Molecular function | channel regulator activity |
Gene name | CACNG5 |
Protein name | Voltage-dependent calcium channel gamma-5 subunit (Neuronal voltage-gated calcium channel gamma-5 subunit) (Transmembrane AMPAR regulatory protein gamma-5) (TARP gamma-5) Calcium voltage-gated channel auxiliary subunit gamma 5 |
Synonyms | |
Description | FUNCTION: Regulates the gating properties of AMPA-selective glutamate receptors (AMPARs). Modulates their gating properties by accelerating their rates of activation, deactivation and desensitization. Displays subunit-specific AMPA receptor regulation. Shows specificity for GRIA1, GRIA4 and the long isoform of GRIA2. Thought to stabilize the calcium channel in an inactivated (closed) state (By similarity). . |
Accessions | ENST00000673855.1 Q9UF02 ENST00000307139.4 ENST00000533854.6 A0A669KBF6 |